Alnylam Pharmaceuticals, Inc. vs Iovance Biotherapeutics, Inc.: Strategic Focus on R&D Spending

Biotech Giants: Alnylam vs. Iovance in R&D Spending

__timestampAlnylam Pharmaceuticals, Inc.Iovance Biotherapeutics, Inc.
Wednesday, January 1, 20141902490002704597
Thursday, January 1, 201527649500015470000
Friday, January 1, 201638239200028037000
Sunday, January 1, 201739063500071615000
Monday, January 1, 201850542000099828000
Tuesday, January 1, 2019655114000166023000
Wednesday, January 1, 2020654819000201727000
Friday, January 1, 2021792156000259039000
Saturday, January 1, 2022883015000294781000
Sunday, January 1, 20231004415000344077000
Monday, January 1, 20241126232000
Loading chart...

Unlocking the unknown

Strategic R&D Investments: Alnylam vs. Iovance

In the competitive landscape of biotechnology, strategic investment in research and development (R&D) is crucial for innovation and growth. Alnylam Pharmaceuticals, Inc. and Iovance Biotherapeutics, Inc. exemplify this focus, with Alnylam consistently outspending Iovance in R&D over the past decade. Since 2014, Alnylam's R&D expenses have surged by over 400%, reaching a peak in 2023. In contrast, Iovance's R&D spending, while also growing, has increased by approximately 127% during the same period. This disparity highlights Alnylam's aggressive pursuit of innovation, potentially positioning it as a leader in the biotech sector. The data underscores the importance of R&D in driving advancements and maintaining a competitive edge in the rapidly evolving field of biotechnology.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025